a-LEN-drone-ate
REMS
Absorption: Poorly absorbed (0.6–0.8%) after oral administration.
Distribution: Transiently distributes to soft tissue, then distributes to bone.
Half-Life: 10 yr (reflects release of drug from skeleton).
(inhibition of bone resorption)
| ROUTE | ONSET | PEAK | DURATION |
|---|---|---|---|
| PO | 1 mo | 3–6 mo | 3 wk–7 mo‡ |
‡After discontinuation of alendronate.
Contraindicated in:
Use Cautiously in:
Derm: erythema, photosensitivity, rash
EENT: blurred vision, conjunctivitis, eye pain/inflammation
GI: abdominal distention, abdominal pain, acid regurgitation, constipation, diarrhea, dyspepsia, dysphagia, esophageal cancer, esophageal ulcer, esophagitis, flatulence, gastritis, nausea, taste perversion, vomiting
MS: musculoskeletal pain, femur fractures, osteonecrosis (primarily of jaw)
Neuro: headache
Resp: asthma exacerbation
Drug-drug:
Treatment of Osteoporosis
Prevention of Osteoporosis
Treatment of Corticosteroid-Induced Osteoporosis in Men and Women
Lab Test Considerations:
NDC Code
